文献速递细菌感染、耐药与抗菌药物

适用于所有肺炎患者的治疗策略:基于多重耐药病原体危险因素选择初始经验性治疗的3年前瞻性多中心队列研究

A Therapeutic Strategy for All Pneumonia Patients: A 3-Year Prospective Multicenter Cohort Study Using Risk Factors for Multidrug-resistant Pathogens to Select Initial Empiric Therapy.
PubMed 文献 · Clin Infect Dis · 2019-01-01

该前瞻性多中心队列研究纳入1089例肺炎患者(社区获得性肺炎656例、医疗保健相关肺炎238例、医院获得性肺炎140例、呼吸机相关性肺炎55例),按基于多重耐药危险因素的治疗算法给予经验性治疗。约83%患者按算法治疗,4.3%治疗不适当;多重耐药病原体频率随肺炎类型而异,≥2个危险因素者多重耐药病原体更多(25.8% vs 5.3%,P<.001),30天死亡率在0-1个危险因素者中更低(4.5% vs 12.5%,P<.001)。结论认为个体多重耐药危险因素可用于统一算法指导所有肺炎患者的经验性治疗,且比肺炎获得场所分类更重要。

要点

  • 约83%患者按多重耐药危险因素算法治疗,4.3%接受不适当治疗。
  • ≥2个多重耐药危险因素者多重耐药病原体占25.8%,0-1个者占5.3%(P<.001)。
  • 0-1个多重耐药危险因素者30天死亡率4.5%,≥2个者12.5%(P<.001)。

核心结论

  • 个体多重耐药危险因素可用于统一算法指导并简化所有肺炎患者的经验性治疗,且在决定30天死亡率方面比肺炎获得场所分类更重要。

研究设计与样本

  • 前瞻性多中心队列研究,纳入1089例肺炎患者,其中社区获得性肺炎656例、医疗保健相关肺炎238例、医院获得性肺炎140例、呼吸机相关性肺炎55例。
  • 研究基于多重耐药危险因素应用治疗算法选择初始经验性治疗。

主要发现

  • 约83%患者按算法治疗,4.3%接受不适当治疗。
  • 多重耐药病原体频率分别为呼吸机相关性肺炎50.9%、医院获得性肺炎27.9%、医疗保健相关肺炎10.9%、社区获得性肺炎5.2%。
  • ≥2个多重耐药危险因素者多重耐药病原体占25.8%,0-1个者占5.3%(P<.001)。
  • 30天死亡率分别为呼吸机相关性肺炎18.2%、医院获得性肺炎13.6%、医疗保健相关肺炎6.7%、社区获得性肺炎4.7%;0-1个多重耐药危险因素者4.5%,≥2个者12.5%(P<.001)。
  • 多因素logistic回归分析中,5个危险因素(高龄、血细胞比容<30%、营养不良、脱水、慢性肝病)以及低血压和不适当治疗与30天死亡率显著相关,而肺炎类型分类(呼吸机相关性肺炎、医院获得性肺炎、医疗保健相关肺炎、社区获得性肺炎)则无关。

关键数值与推荐

  • 多重耐药危险因素包括高龄、血细胞比容<30%、营养不良、脱水、慢性肝病。
  • ≥2个多重耐药危险因素者多重耐药病原体频率25.8%,0-1个者5.3%(P<.001)。
  • 0-1个多重耐药危险因素者30天死亡率4.5%,≥2个者12.5%(P<.001)。

临床怎么用

  • 原文结论认为个体多重耐药危险因素可用于统一算法指导并简化所有肺炎患者的经验性治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Empiric therapy of pneumonia is currently based on the site of acquisition (community or hospital), but could be chosen, based on risk factors for multidrug-resistant (MDR) pathogens, independent of site of acquisition. METHODS: We prospectively applied a therapeutic algorithm based on MDR risks, in a multicenter cohort study of 1089 patients with 656 community-acquired pneumonia (CAP), 238 healthcare-associated pneumonia (HCAP), 140 hospital-acquired pneumonia (HAP), or 55 ventilator-associated pneumonia (VAP). RESULTS: Approximately 83% of patients were treated according to the algorithm, with 4.3% receiving inappropriate therapy. The frequency of MDR pathogens varied, respectively, with VAP (50.9%), HAP (27.9%), HCAP (10.9%), and CAP (5.2%). Those with ≥2 MDR risks had MDR pathogens more often than those with 0-1 MDR risk (25.8% vs 5.3%, P < .001). The 30-day mortality rates were as follows: VAP (18.2%), HAP (13.6%), HCAP (6.7%), and CAP (4.7%), and were lower in patients with 0-1 MDR risks than in those with ≥2 MDR risks (4.5% vs 12.5%, P < .001). In multivariate logistic regression analysis, 5 risk factors (advanced age, hematocrit <30%, malnutrition, dehydration, and chronic liver disease), as well as hypotension and inappropriate therapy were significantly correlated with 30-day mortality, whereas the classification of pneumonia type (VAP, HAP, HCAP, CAP) was not. CONCLUSIONS: Individual MDR risk factors can be used in a unified algorithm to guide and simplify empiric therapy for all pneumonia patients, and were more important than the classification of site of pneumonia acquisition in determining 30-day mortality. CLINICAL TRIALS REGISTRATION: JMA-IIA00146.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Maruyama T, Fujisawa T, Ishida T, et al. A Therapeutic Strategy for All Pneumonia Patients: A 3-Year Prospective Multicenter Cohort Study Using Risk Factors for Multidrug-resistant Pathogens to Select Initial Empiric Therapy. Clin Infect Dis. 2019. PMID: 30084884. doi:10.1093/cid/ciy631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。